Earnings

Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026

Oct 19, 2026 · 08:37 AM ET· updated 1h ago

Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology imagesTempus AI, Inc. (NASDAQ:TEM) today announced

Why It Matters

Tempus AI tested a tool that uses computer vision to find cancer markers faster. This showed the tool works well, which could help doctors treat patients better.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

TEM63.87

-0.85 (-1.31%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.